Ibrutinib for treatment of autoimmune cytopenia after hematopoietic stem cell transplantation: report of 2 cases and literature review

Objective To explore the curative effect of ibrutinib in treatment of autoimmune cytopenia (AIC) after hematopoietic stem cell transplantation (HSCT). Methods Two leukemia patients receiving HSCT at our hospital in 2016 and 2018 respectively were enrolled in this study, who were subsequently diagno...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	WEI Ruowen, CHEN Wenlan, XIE Rong, XIA Linghui, YOU Yong
Formato:	article
Lenguaje:	ZH
Publicado:	Editorial Office of Journal of Third Military Medical University 2021
Materias:	ibrutinib hematopoietic stem cell transplantation autoimmune cytopenia pure red cell aplastic anemia autoimmune hemolytic anemia evans syndrome Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f3a8d1dd777d44119a782ffca3a57081
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f3a8d1dd777d44119a782ffca3a57081
record_format	dspace
spelling	oai:doaj.org-article:f3a8d1dd777d44119a782ffca3a570812021-11-12T04:52:50ZIbrutinib for treatment of autoimmune cytopenia after hematopoietic stem cell transplantation: report of 2 cases and literature review10.16016/j.1000-5404.2021080281000-5404https://doaj.org/article/f3a8d1dd777d44119a782ffca3a570812021-11-01T00:00:00Zhttp://aammt.tmmu.edu.cn/Upload/rhtml/202108028.htmhttps://doaj.org/toc/1000-5404 Objective To explore the curative effect of ibrutinib in treatment of autoimmune cytopenia (AIC) after hematopoietic stem cell transplantation (HSCT). Methods Two leukemia patients receiving HSCT at our hospital in 2016 and 2018 respectively were enrolled in this study, who were subsequently diagnosed as Evans syndrome (case 2) and pure red cell aplastic Anemia (PRCA) (case 1) respectively after transplantation. Due to failing to the treatment of glucocorticoid, immunoglobulin, immunosuppressants, plasma exchange and blood transfusion support, ibrutinib was tentatively applied to the patients, and its therapeutic effects and the changes of immune indexes were observed. Results After ibrutinib treatment, case 1 needed fewer times of red blood cell transfusion than before, with decreased level of anti-donor blood group antibodies and gradually elevated hemoglobin level. She was gradually relieved of blood transfusion, and then achieved complete remission about 3 months after the treatment. As for case 2, she was released from platelet infusion approximately 2 weeks after the ibrutinib treatment, with progressively improved hemoglobin level and platelet count, got weakly positive result to direct antiglobulin test (DAT) and negative result to autoantibodies, and achieved complete remission as well. No obvious adverse drug reactions or recurrence of primary disease were observed in the 2 patients. Conclusion Ibrutinib has certain efficacy in the treatment for PRCA or Evans syndrome after HSCT.WEI RuowenCHEN Wenlan XIE Rong XIA LinghuiYOU YongEditorial Office of Journal of Third Military Medical Universityarticleibrutinibhematopoietic stem cell transplantationautoimmune cytopeniapure red cell aplastic anemiaautoimmune hemolytic anemiaevanssyndromeMedicine (General)R5-920ZHDi-san junyi daxue xuebao, Vol 43, Iss 21, Pp 2337-2342 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	ibrutinib hematopoietic stem cell transplantation autoimmune cytopenia pure red cell aplastic anemia autoimmune hemolytic anemia evans syndrome Medicine (General) R5-920
spellingShingle	ibrutinib hematopoietic stem cell transplantation autoimmune cytopenia pure red cell aplastic anemia autoimmune hemolytic anemia evans syndrome Medicine (General) R5-920 WEI Ruowen CHEN Wenlan XIE Rong XIA Linghui YOU Yong Ibrutinib for treatment of autoimmune cytopenia after hematopoietic stem cell transplantation: report of 2 cases and literature review
description	Objective To explore the curative effect of ibrutinib in treatment of autoimmune cytopenia (AIC) after hematopoietic stem cell transplantation (HSCT). Methods Two leukemia patients receiving HSCT at our hospital in 2016 and 2018 respectively were enrolled in this study, who were subsequently diagnosed as Evans syndrome (case 2) and pure red cell aplastic Anemia (PRCA) (case 1) respectively after transplantation. Due to failing to the treatment of glucocorticoid, immunoglobulin, immunosuppressants, plasma exchange and blood transfusion support, ibrutinib was tentatively applied to the patients, and its therapeutic effects and the changes of immune indexes were observed. Results After ibrutinib treatment, case 1 needed fewer times of red blood cell transfusion than before, with decreased level of anti-donor blood group antibodies and gradually elevated hemoglobin level. She was gradually relieved of blood transfusion, and then achieved complete remission about 3 months after the treatment. As for case 2, she was released from platelet infusion approximately 2 weeks after the ibrutinib treatment, with progressively improved hemoglobin level and platelet count, got weakly positive result to direct antiglobulin test (DAT) and negative result to autoantibodies, and achieved complete remission as well. No obvious adverse drug reactions or recurrence of primary disease were observed in the 2 patients. Conclusion Ibrutinib has certain efficacy in the treatment for PRCA or Evans syndrome after HSCT.
format	article
author	WEI Ruowen CHEN Wenlan XIE Rong XIA Linghui YOU Yong
author_facet	WEI Ruowen CHEN Wenlan XIE Rong XIA Linghui YOU Yong
author_sort	WEI Ruowen
title	Ibrutinib for treatment of autoimmune cytopenia after hematopoietic stem cell transplantation: report of 2 cases and literature review
title_short	Ibrutinib for treatment of autoimmune cytopenia after hematopoietic stem cell transplantation: report of 2 cases and literature review
title_full	Ibrutinib for treatment of autoimmune cytopenia after hematopoietic stem cell transplantation: report of 2 cases and literature review
title_fullStr	Ibrutinib for treatment of autoimmune cytopenia after hematopoietic stem cell transplantation: report of 2 cases and literature review
title_full_unstemmed	Ibrutinib for treatment of autoimmune cytopenia after hematopoietic stem cell transplantation: report of 2 cases and literature review
title_sort	ibrutinib for treatment of autoimmune cytopenia after hematopoietic stem cell transplantation: report of 2 cases and literature review
publisher	Editorial Office of Journal of Third Military Medical University
publishDate	2021
url	https://doaj.org/article/f3a8d1dd777d44119a782ffca3a57081
work_keys_str_mv	AT weiruowen ibrutinibfortreatmentofautoimmunecytopeniaafterhematopoieticstemcelltransplantationreportof2casesandliteraturereview AT chenwenlan ibrutinibfortreatmentofautoimmunecytopeniaafterhematopoieticstemcelltransplantationreportof2casesandliteraturereview AT xierong ibrutinibfortreatmentofautoimmunecytopeniaafterhematopoieticstemcelltransplantationreportof2casesandliteraturereview AT xialinghui ibrutinibfortreatmentofautoimmunecytopeniaafterhematopoieticstemcelltransplantationreportof2casesandliteraturereview AT youyong ibrutinibfortreatmentofautoimmunecytopeniaafterhematopoieticstemcelltransplantationreportof2casesandliteraturereview
_version_	1718431204549591040

Ibrutinib for treatment of autoimmune cytopenia after hematopoietic stem cell transplantation: report of 2 cases and literature review

Ejemplares similares